Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and ...

People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

A new study suggests a common eye condition could be quietly masking one of the only early warning signs of bladder cancer — ...

Study suggests inability to identify blood in urine may delay diagnosis and reduce surviva ...

A study led by Stanford Medicine found that the earliest sign of bladder cancer — blood in the urine — may be invisible to people who are colorblind, increasing their risk of dying from the disease.

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

Discover how urinary microRNA biomarkers can non-invasively identify aggressive bladder cancer subtypes. Read more on this ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.